JP2002502412A - ５−ナフタレン−１−イル−１，３−ジオキサン誘導体、製造方法および治療用途 - Google Patents

５−ナフタレン−１−イル−１，３−ジオキサン誘導体、製造方法および治療用途

Info

Publication number
JP2002502412A
JP2002502412A JP50172399A JP50172399A JP2002502412A JP 2002502412 A JP2002502412 A JP 2002502412A JP 50172399 A JP50172399 A JP 50172399A JP 50172399 A JP50172399 A JP 50172399A JP 2002502412 A JP2002502412 A JP 2002502412A
Authority
JP
Japan
Prior art keywords
group
general formula
mixture
naphthyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP50172399A
Other languages
English (en)
Japanese (ja)
Inventor
ダルガザンリ，ジア
ラルデノア，パトリック
フロスト，ジョナサン
ジョルジュ，パスカル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9706944A external-priority patent/FR2764287B1/fr
Priority claimed from FR9706947A external-priority patent/FR2764291B1/fr
Priority claimed from FR9706945A external-priority patent/FR2764288B1/fr
Priority claimed from FR9706946A external-priority patent/FR2764289B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of JP2002502412A publication Critical patent/JP2002502412A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP50172399A 1997-06-05 1998-06-03 ５−ナフタレン−１−イル−１，３−ジオキサン誘導体、製造方法および治療用途 Pending JP2002502412A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
FR97/06944 1997-06-05
FR97/06947 1997-06-05
FR9706944A FR2764287B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique
FR97/06946 1997-06-05
FR9706947A FR2764291B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR9706945A FR2764288B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
FR97/06945 1997-06-05
FR9706946A FR2764289B1 (fr) 1997-06-05 1997-06-05 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique
PCT/FR1998/001113 WO1998055474A1 (fr) 1997-06-05 1998-06-03 Derives de 5-naphtalen-1-yl-1,3-dioxane, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
JP2002502412A true JP2002502412A (ja) 2002-01-22

Family

ID=27447000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50172399A Pending JP2002502412A (ja) 1997-06-05 1998-06-03 ５−ナフタレン−１−イル−１，３−ジオキサン誘導体、製造方法および治療用途

Country Status (18)

Country Link
EP (1) EP0986552A1 (de)
JP (1) JP2002502412A (de)
KR (1) KR20010013435A (de)
CN (1) CN1265658A (de)
AR (1) AR012908A1 (de)
AU (1) AU8025198A (de)
BG (1) BG103937A (de)
BR (1) BR9810742A (de)
CA (1) CA2290695A1 (de)
CO (1) CO4940480A1 (de)
EE (1) EE9900560A (de)
HU (1) HUP0002166A3 (de)
IL (1) IL133242A0 (de)
NO (1) NO995966L (de)
PL (1) PL337234A1 (de)
SK (1) SK166199A3 (de)
TR (1) TR199903022T2 (de)
WO (1) WO1998055474A1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504362A (ja) * 2000-07-21 2004-02-12 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経障害性疼痛ならびに群発性頭痛および偏頭痛に関連する疼痛の予防もしくは治療における使用のためのカルバメート化合物
JP2005539045A (ja) * 2002-08-29 2005-12-22 サノフィ−アベンティス ジオキサン−２−アルキルカルバメート誘導体、その製造法および治療における適用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0461958T3 (da) * 1990-06-15 1995-02-20 Synthelabo 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i terapien
FR2714055B1 (fr) * 1993-12-22 1996-01-19 Synthelabo Dérivés de 5-(arylalkyl)-1,3-dioxane substitués en position 2, leur préparation et leur utilisation en thérapeutique.
FR2742152B1 (fr) * 1995-12-06 1998-01-16 Synthelabo Derives de 5-naphtalen-1-yl-1,3-dioxanes, leur preparation et leur application en therapeutique

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504362A (ja) * 2000-07-21 2004-02-12 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経障害性疼痛ならびに群発性頭痛および偏頭痛に関連する疼痛の予防もしくは治療における使用のためのカルバメート化合物
JP2005539045A (ja) * 2002-08-29 2005-12-22 サノフィ−アベンティス ジオキサン−２−アルキルカルバメート誘導体、その製造法および治療における適用
JP2010248218A (ja) * 2002-08-29 2010-11-04 Sanofi-Aventis ジオキサン−２−アルキルカルバメート誘導体の製造法およびその中間体

Also Published As

Publication number Publication date
BG103937A (en) 2000-07-31
NO995966D0 (no) 1999-12-03
HUP0002166A2 (hu) 2001-06-28
BR9810742A (pt) 2000-09-12
SK166199A3 (en) 2000-06-12
CO4940480A1 (es) 2000-07-24
IL133242A0 (en) 2001-03-19
AR012908A1 (es) 2000-11-22
EE9900560A (et) 2000-06-15
CA2290695A1 (en) 1998-12-10
NO995966L (no) 2000-02-04
PL337234A1 (en) 2000-08-14
HUP0002166A3 (en) 2002-12-28
EP0986552A1 (de) 2000-03-22
WO1998055474A1 (fr) 1998-12-10
CN1265658A (zh) 2000-09-06
AU8025198A (en) 1998-12-21
TR199903022T2 (xx) 2000-04-21
KR20010013435A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
JP4861979B2 (ja) テトラヒドロイソキノリンスルホンアミド誘導体、その調製及び治療における同誘導体の使用
HU222724B1 (hu) Eljárás 3-amino-2-fenil-piperidin elżállítására
JPH03176469A (ja) イソインドロン誘導体
FR2696178A1 (fr) Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
EP1019373B1 (de) 1-acyl-3-phenyl-3-(3-piperidinopropyl)piperidin-derivate als für den menschlichen nk3-rezeptor selektive antagonisten
JPS6013788A (ja) 新規なクマリン誘導体
JP5165578B2 (ja) イソキノリンおよびベンゾ［ｈ］イソキノリン誘導体、調製およびヒスタミンｈ３受容体のアンタゴニストとしてのこの治療上の使用
JP2011500728A (ja) 疾患の処置に有用なニコチン性アセチルコリン受容体の（１，４−ジアザ−ビシクロ［３．２．２］ノン−６−エン−４−イル）−ヘテロシクリル−メタノンリガンド
JPH05186460A (ja) ２−（１−ピペリジル）エタノール誘導体、その製造方法およびその治療への適用
JPH11503126A (ja) 新規な複素環式化合物
JPS59161377A (ja) ピペリジンジオン誘導体、その製造方法及びそれを含む薬剤
JPH07133273A (ja) 光学活性イミダゾリジノン誘導体とその製造方法
JP2002502412A (ja) ５−ナフタレン−１−イル−１，３−ジオキサン誘導体、製造方法および治療用途
EP0929550A1 (de) N-(benzothiazol-2-yl)piperidine-1-ethanamine derivate, ihre herstellung und therapeutische verwendung
JPH07233162A (ja) イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬
JP2002501920A (ja) セロトニン−１ａ受容体作動薬としてのオキサゾール誘導体
JPH01186866A (ja) 分割化アミノピロリジン神経防護剤
EP1192152B1 (de) Fluorierte benzodioxan imidazolin derivate, deren herstellung und deren therapeutische verwendung
JP2002537288A (ja) ドーパミンｄ１受容体アゴニスト化合物
JP2001512491A (ja) １−（イソキノリン−１−イル）−４−（１−フェニメチル）ピペラジン；ドーパミン受容体サブタイプ特異的リガンド
FR2862968A1 (fr) Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
MXPA99011203A (en) 5-naphthalen-1-yl-1,3-dioxane derivatives, preparation and therapeutic application
JP6808088B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストとしてのフルオロピペリジン化合物
JPS6157582A (ja) 新規なベンゾジアゼピン類
JP2003507323A (ja) １，４−ジアザシクロヘプタン化合物、その製造方法およびその薬剤としての使用